A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Novo, searching for a spark, spotlights new data for three-pronged obesity drug
Novo, searching for a spark, spotlights new data for three-pronged obesity drug
Slate starts up with $130M and a headache drug from China
Slate starts up with $130M and a headache drug from China
FDA fleshes out new roadmap for testing personalized therapies
FDA fleshes out new roadmap for testing personalized therapies
Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Merck to split cancer, specialty drug businesses in leadership shakeup
Merck to split cancer, specialty drug businesses in leadership shakeup
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy
All about cell therapy process characterization
All about cell therapy process characterization
Grail’s multi-cancer early detection test misses study goal
Grail’s multi-cancer early detection test misses study goal
Supreme Court invalidates Trump tariffs based on emergency powers
Supreme Court invalidates Trump tariffs based on emergency powers
Roche gets FDA decision date on closely watched breast cancer drug
Roche gets FDA decision date on closely watched breast cancer drug
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
AI is slashing jobs across industries. Will pharma be next?
AI is slashing jobs across industries. Will pharma be next?
Altesa, run by former Trump official, raises $75M for well-traveled lung drug
Altesa, run by former Trump official, raises $75M for well-traveled lung drug
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6
Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6
FDA accepts BMS protein degrader for review; Disc rare disease drug rejected
FDA accepts BMS protein degrader for review; Disc rare disease drug rejected
An Alzheimer’s startup emerges with $175M in venture backing
An Alzheimer’s startup emerges with $175M in venture backing
Psychedelics stocks rise as Compass’ psilocybin drug heads to FDA
Psychedelics stocks rise as Compass’ psilocybin drug heads to FDA
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page